A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285
This study is recruiting at 14 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumor, Adult
- Non-small Cell Lung Cancer
- Melanoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Pierre Fabre Medicament
- Last updated on ClinicalTrials.gov
- September 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 4
- The Angeles Clinic · Los Angeles, CA
- UCLA · Los Angeles, CA
- University of California San Diego, Moores Cancer Center · San Diego, CA
- University of California San Francisco · San Francisco, CA
Colorado · 1
- Sarah Cannon Research Institute Denver · Denver, CO
Florida · 2
- Mayo Clinic - Florida · Jacksonville, FL
- Sarah Cannon Research Institute - Florida Cancer Specialists · Orlando, FL
Minnesota · 1
- Mayo Clinic - Rochester · Rochester, MN
New Jersey · 2
- Atlantic Health · Morristown, NJ
- Rutgers Cancer Institute of New Jersey · New Brunswick, NJ
New York · 1
- NYU Langone · New York, NY
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Tennessee · 1
- Sarah Cannon Research Institute-Tennessee Oncology · Nashville, TN
Virginia · 1
- Virginia Cancer Specialists · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.